Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.
Aged
Carcinoma, Renal Cell
/ drug therapy
Chemotherapy, Adjuvant
Disease-Free Survival
Female
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Neovascularization, Pathologic
/ drug therapy
Pharmacogenomic Testing
Risk Factors
Sunitinib
/ administration & dosage
Vascular Endothelial Growth Factor Receptor-1
/ genetics
Vascular Endothelial Growth Factor Receptor-2
/ genetics
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 02 2019
15 02 2019
Historique:
received:
17
07
2018
revised:
28
08
2018
accepted:
02
11
2018
pubmed:
8
11
2018
medline:
21
4
2020
entrez:
8
11
2018
Statut:
ppublish
Résumé
In the S-TRAC trial, adjuvant sunitinib prolonged disease-free survival (DFS) versus placebo in patients with loco-regional renal cell carcinoma at high risk of recurrence after nephrectomy. An exploratory analysis evaluated associations between SNPs in several angiogenesis- or hypoxia-related genes and clinical outcomes in S-TRAC. Blood samples were genotyped for 10 SNPs and one insertion/deletion mutation using TaqMan assays. DFS was compared using log-rank tests for each genotype in sunitinib versus placebo groups and between genotypes within each of three (sunitinib, placebo, and combined sunitinib plus placebo) treatment groups. In all, 286 patients (sunitinib, Correlations between
Identifiants
pubmed: 30401688
pii: 1078-0432.CCR-18-1724
doi: 10.1158/1078-0432.CCR-18-1724
pmc: PMC6669904
mid: NIHMS1512002
doi:
Substances chimiques
KDR protein, human
EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-1
EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-2
EC 2.7.10.1
Sunitinib
V99T50803M
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1165-1173Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
©2018 American Association for Cancer Research.
Références
Eur Urol. 2015 Oct;68(4):621-9
pubmed: 25930089
Expert Rev Mol Diagn. 2016;16(5):605-18
pubmed: 26837796
Br J Cancer. 2004 Feb 23;90(4):747-51
pubmed: 14970847
Lancet Oncol. 2011 Nov;12(12):1143-50
pubmed: 22015057
Clin Cancer Res. 2018 Sep 15;24(18):4407-4415
pubmed: 29773662
Urol Oncol. 2017 Aug;35(8):529.e9-529.e16
pubmed: 28385611
J Clin Oncol. 2004 Aug 15;22(16):3316-22
pubmed: 15310775
CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):604-613
pubmed: 28571114
Acta Oncol. 2014 Jan;53(1):103-12
pubmed: 23421954
BJU Int. 2016 Dec;118(6):890-901
pubmed: 27417418
Clin Genitourin Cancer. 2015 Aug;13(4):328-337.e3
pubmed: 25816720
J Clin Oncol. 2011 Jun 20;29(18):2557-64
pubmed: 21576632
N Engl J Med. 2016 Dec 8;375(23):2246-2254
pubmed: 27718781
J Urol. 2005 Jan;173(1):48-51
pubmed: 15592023
Br J Cancer. 2013 Mar 19;108(5):1126-32
pubmed: 23511629
Clin Pharmacol Ther. 2012 Oct;92(4):503-10
pubmed: 22948895
J Cancer Res Clin Oncol. 2016 Jun;142(6):1171-82
pubmed: 26935927
J Urol. 2000 Apr;163(4):1090-5; quiz 1295
pubmed: 10737472
Eur J Clin Pharmacol. 2015 Dec;71(12):1477-84
pubmed: 26387812
J Urol. 2005 Aug;174(2):466-72; discussion 472; quiz 801
pubmed: 16006866
Clin Genitourin Cancer. 2017 Oct;15(5):526-533
pubmed: 28330808
Clin Cancer Res. 2018 Apr 1;24(7):1554-1561
pubmed: 29374054
Pharmacogenet Genomics. 2017 Jun;27(6):227-231
pubmed: 28430711
J Clin Oncol. 2001 Mar 15;19(6):1649-57
pubmed: 11250993
Cancer Chemother Pharmacol. 2013 Oct;72(4):825-35
pubmed: 24013576
Cancer Chemother Pharmacol. 2014 Oct;74(4):739-50
pubmed: 25100134
Clin Cancer Res. 2011 Feb 1;17(3):620-9
pubmed: 21097692
Oncotarget. 2017 Mar 7;8(10):16887-16898
pubmed: 28129643
Br J Cancer. 2016 Oct 25;115(9):1147-1155
pubmed: 27727232
Cancer. 2003 Apr 1;97(7):1663-71
pubmed: 12655523
Eur Urol. 2018 Jan;73(1):62-68
pubmed: 28967554